LAWRENCE, Mass., Aug. 8, 2016 NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, today announced the release of new enhanced priming features, the first of many upcoming capabilities of its next generation hemodialysis system. The features are designed to be used for home treatments with current and next generations of the NxStage System One.
"We're excited to be providing patients and customers with access to these new features that deliver on our promise to reduce the amount of time and effort involved for patients to set up their System One for treatment," said Joseph E. Turk, president of NxStage. "These features improve the overall ease of use of the System One and are the first of many new features and capabilities to come to support our NxGen system."
The new priming features are immediately available in the United States. For more information, please visit www.nxstage.com.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and simplify alternative site care. The System One is also used to provide a range of flexible therapy options in more traditional care settings such as hospitals and dialysis centers. Its safety and efficacy have been demonstrated by experience with more than 13 million treatments with thousands of patients around the world. http://www.nxstage.com/.
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage has also established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's website at http://www.nxstage.com and www.nxstagekidneycare.com.
Forward Looking Statements
This release contains forward-looking statements concerning our business, operations and financial condition. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated release of future NxGen product features and capabilities. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products domestically and internationally, regulatory approvals, unanticipated difficulties in achieving development objectives or timelines, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.
Kristen K. Sheppard, Esq.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-launches-first-of-many-nxgen-features-and-capabilities-300309866.html
SOURCE NxStage Medical, Inc.